Two Connecticut settlements announced on May 6, 2026, with Radiance Medspa and Made-in-China place weight-loss injection advertising, prescribing, and compounded-drug claims within the state’s GLP-1 enforcement activity.
Attorney General Tong Announces GLP-1 Settlements Involving Online Platform and Med Spa
On May 6, 2026, Connecticut Attorney General William Tong announced a settlement with Radiance Medspa of Avon involving advertising and prescribing non-FDA-approved compounded semaglutide and/or tirzepatide weight-loss injections. The announcement also included a settlement with Made-in-China, an international trade platform investigated for unlawful “research grade” GLP-1 sales to U.S. consumers without prescriptions or medical oversight. For Med Spa operators offering weight-loss injections, the action is relevant because it addresses GLP-1 advertising, prescribing practices, compounded-drug claims, and consumer-facing representations for services commonly marketed in aesthetic and wellness settings.
Key Details of the Weight-Loss Drug Sales and Advertising Settlements
Connecticut Attorney General William Tong announced separate GLP-1-related settlements on May 6, 2026, involving Made-in-China and Radiance Medspa of Avon. Building on Connecticut’s prior enforcement activity involving compounded drugs and Med Spas, the settlements address online “research grade” GLP-1 sales, compounded weight-loss injection advertising, and prescribing practices tied to non-FDA-approved semaglutide and/or tirzepatide products.
The Made-in-China settlement follows a May 2025 investigation into the international trade platform’s sale of “research grade” GLP-1 products to Connecticut consumers without prescriptions or medical oversight. Under the agreement, manufacturers may no longer use the platform to advertise or sell GLP-1 products to U.S. customers. Made-in-China must also use a monitoring system to identify and remove GLP-1 listings within five days. The platform is subject to a $300,000 penalty, suspended after $30,000, with additional penalties possible for settlement violations.
The Radiance Medspa settlement addresses a separate issue involving advertising and prescribing non-FDA-approved compounded semaglutide and/or tirzepatide weight-loss injections. The Attorney General’s Office said the settlement follows May 2025 warning letters sent to Connecticut clinics and Med Spas regarding the marketing of GLP-1 drugs produced by compounding pharmacies. Those letters cited FDA-identified concerns involving dosing errors, salt forms sourced from overseas factories with spotty inspection records, and adverse event reports, including some requiring medical intervention.
The May 6 announcement also referenced a 2025 settlement with Triggered Brand, which resolved a Connecticut lawsuit alleging unlawful sales of “research grade” GLP-1 weight-loss drugs. Under that agreement, Triggered Brand was required to stop sales of bootleg GLP-1 weight-loss drugs and was subject to a $300,000 judgment, suspended after $18,500. Attorney General Tong stated that additional enforcement actions are active and ongoing.
Source Attribution
According to a May 6, 2026, press release from the Connecticut Office of the Attorney General, the settlements involved Made-in-China and Radiance Medspa of Avon. The release also referenced earlier GLP-1 enforcement activity from May 2025, including the Triggered Brand lawsuit, the Made-in-China investigation, and warning letters sent to Connecticut clinics and Med Spas regarding compounded weight-loss drug marketing.
Compliance Context for GLP-1 Advertising and Weight-Loss Injection Services
The Connecticut settlements place GLP-1 weight-loss services within drug-sourcing, advertising, and prescribing compliance. For Med Spa operators, the action is relevant because weight-loss injection programs are medical services involving patient-facing claims, pharmacy relationships, clinical evaluation, prescription authority, and treatment records.
Advertising language is central to the Connecticut action. The Attorney General’s Office identified concerns involving claims that compounded GLP-1 products were marketed as “generic” versions of Ozempic, Wegovy, Mounjaro, or Zepbound, or as FDA-approved alternatives. In related federal enforcement, FDA warning letters involving telehealth GLP-1 marketing cited false or misleading claims tied to compounded GLP-1 products.
The Connecticut action identifies several compliance areas for Med Spa operators offering GLP-1 services, including advertising claims, compounded-drug sourcing, prescribing practices, and documentation tied to patient evaluation and treatment. The Attorney General’s statement that no generic GLP-1 weight-loss injections are currently on the market is directly relevant to patient-facing claims that describe compounded products as generic or equivalent alternatives to branded drugs.
Separately, the FDA’s April 30, 2026, 503B bulks-list proposal adds federal context to the distinction between FDA-approved GLP-1 medications and compounded products marketed for weight-loss treatment. The FDA is accepting public comments through June 29, 2026, before making a final determination.
Practical Implications for Med Spa Operators
Based on the Connecticut enforcement action, key compliance considerations include:
- Distinguish compounded GLP-1 products from FDA-approved branded medications in patient-facing materials, especially when referencing Ozempic, Wegovy, Mounjaro, or Zepbound.
- Audit GLP-1 service pages, consent forms, intake materials, and treatment descriptions for claims that imply compounded products are “generic” or FDA-approved alternatives.
- Verify that pharmacy sourcing, prescription records, and patient documentation identify the source of any compounded GLP-1 products used in treatment.
- Confirm that GLP-1 treatment workflows identify patient evaluation, prescribing authority, and follow-up documentation for weight-loss injection services.
- Maintain records showing how GLP-1 services are sourced, prescribed, documented, and communicated to all patients.
What to Watch Next
Attorney General Tong stated that additional enforcement actions are active and ongoing. New developments may provide further information for Med Spa operators offering GLP-1 weight-loss services, particularly around compounded-drug advertising, sourcing, prescribing, and documentation. FDA action on the April 30, 2026, proposal may also provide additional federal guidance on compounded GLP-1 oversight.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Connecticut State Capitol in Hartford” by EGryk, via Wikimedia Commons, licensed under CC BY-SA 4.0.
